PMID: 826950Nov 10, 1976

Blockade of the discriminative effects of morphine in the rat by naltrexone and naloxone

Psychopharmacology
H E Shannon, Stephen G Holtzman

Abstract

The capacity of the specific narcotic antagonists naltrexone and naloxone to block the discriminative effects produced by morphine in the rat were evaluated using a two-choice, discrete-trial avoidance task. The antagonists produced a dose-dependent and time-dependent blockade of morphine's effects as measured by responding on the morphine-appropriate choice lever. Naltrexone and naloxone were equipotent when given subcutaneously concomitantly with subcutaneously administered morphine. However, when the antagonists were administered orally at 0, 2, 4 or 8 h prior to s.c. morphine, naltrexone was more potent than naloxone at every time point and had a duration of action at least twice that of oral naloxone. The discriminitive effects of the narcotic analgesics morphine and methadone were also compared after oral and subcutaneous administration. Both drugs produced dose-related discriminative effects and were one-tenth as potent by the oral as by the subcutaneous route of administration. These results suggest that the discriminative effects produced by morphine in the rat can provide an animal model for the quantitative evaluation of the narcotic antagonist properties of drugs that might be considered for use in narcotic antagoni...Continue Reading

References

Nov 21, 1975·Psychopharmacologia·J C Winter
Feb 1, 1973·European Journal of Pharmacology·J A RosecransI D Hirschhorn
Feb 1, 1973·Archives of General Psychiatry·W R MartinR W Carpenter
Jun 1, 1973·Archives of General Psychiatry·W R MartinP A Mansky
Mar 29, 1971·JAMA : the Journal of the American Medical Association·A ZaksA M Freedman
Sep 1, 1968·Clinical Pharmacology and Therapeutics·M FinkA M Freedman
Jul 1, 1966·Clinical Pharmacology and Therapeutics·W R MartinT K McClane

Citations

Nov 15, 1977·Psychopharmacology·I D Hirschhorn
Jul 19, 1978·Psychopharmacology·T U Järbe, C Rollenhagen
Jan 1, 1983·Psychopharmacology·J M White, Stephen G Holtzman
Jan 1, 1979·Psychopharmacology·L G Frey, J C Winter
Oct 1, 1994·Psychopharmacology·T R Levesque, K W Locke
Nov 7, 1980·European Journal of Pharmacology·J J Teal, Stephen G Holtzman
Oct 22, 1982·European Journal of Pharmacology·F C Colpaert
Jan 2, 1985·European Journal of Pharmacology·N A Ator, R R Griffiths
Dec 12, 1989·European Journal of Pharmacology·N NishidaM Fujino
Aug 15, 1977·Life Sciences·H E Shannon, Stephen G Holtzman
Mar 16, 1981·Life Sciences·D R Brown, Stephen G Holtzman
Sep 1, 1978·Neuropharmacology·F C ColpaertP A Janssen
Oct 1, 1978·Pharmacology, Biochemistry, and Behavior·T U Järbe
Oct 1, 1978·Pharmacology, Biochemistry, and Behavior·L L HernandezJ B Appel
Dec 1, 1978·Pharmacology, Biochemistry, and Behavior·F C Colpaert
Jan 1, 1979·Pharmacology, Biochemistry, and Behavior·S L Weibel, H H Wolf
Apr 1, 1979·Pharmacology, Biochemistry, and Behavior·T U JärbeM D Swedberg
Apr 1, 1979·Pharmacology, Biochemistry, and Behavior·Stephen G Holtzman
Apr 1, 1980·Pharmacology, Biochemistry, and Behavior·J J Teal, Stephen G Holtzman
Nov 1, 1981·Pharmacology, Biochemistry, and Behavior·C Advokat
Aug 1, 1982·Pharmacology, Biochemistry, and Behavior·J M WitkinR B Carter
Jan 1, 1984·Pharmacology, Biochemistry, and Behavior·J E ShookW L Dewey
Mar 1, 1986·Pharmacology, Biochemistry, and Behavior·M G Paule, G R Wenger
Feb 1, 1988·Pharmacology, Biochemistry, and Behavior·A H OlivetoL A Dykstra
Jan 1, 1988·Pharmacology, Biochemistry, and Behavior·M Ukai, Stephen G Holtzman
Aug 1, 1989·Pharmacology, Biochemistry, and Behavior·Stephen G Holtzman
Apr 1, 1990·Pharmacology, Biochemistry, and Behavior·S M EvansC E Johanson
Jun 1, 1991·Pharmacology, Biochemistry, and Behavior·A M YoungG Kapitsopoulos
Jan 1, 1992·Pharmacology, Biochemistry, and Behavior·S T SmurthwaiteA L Riley
Jan 1, 1992·Pharmacology, Biochemistry, and Behavior·Glenn W StevensonA L Riley
Feb 1, 1992·Pharmacology, Biochemistry, and Behavior·G J Schaefer, R P Michael
Mar 1, 1994·Pharmacology, Biochemistry, and Behavior·Stephen G HoltzmanW K Schmidt
Aug 1, 1996·Progress in Neuro-psychopharmacology & Biological Psychiatry·K W LockeR L Balster
Jul 19, 2000·Pharmacology, Biochemistry, and Behavior·Stephen G Holtzman
Jan 29, 2002·Pharmacology, Biochemistry, and Behavior·Glenn W StevensonAntony L Riley
Aug 1, 1997·Pharmacology, Biochemistry, and Behavior·Stephen G Holtzman
Oct 9, 1999·Pharmacology, Biochemistry, and Behavior·F C Colpaert
Jan 12, 2002·Brain Research Bulletin·K W Easterling, Stephen G Holtzman
May 7, 2002·Behavioural Pharmacology·I P StolermanA Morley
Feb 4, 2010·The Journal of Pharmacology and Experimental Therapeutics·Keith L Shelton
Jan 1, 1982·Annals of the New York Academy of Sciences·Stephen G Holtzman
May 15, 2015·Journal of Pharmacological and Toxicological Methods·David V GauvinTheodore J Baird
Sep 7, 2018·Drug Development Research·Mario P SgroMark S Todtenkopf
Mar 2, 2010·The Journal of Pharmacology and Experimental Therapeutics·Rajeev I DesaiJack Bergman
Apr 19, 2002·The Journal of Pharmacology and Experimental Therapeutics·M M SchweriStephen G Holtzman
Feb 28, 2003·The Journal of Pharmacology and Experimental Therapeutics·Lawrence P CarterCharles P France
Mar 1, 1994·Journal of the Experimental Analysis of Behavior·R J Lamb, J E Henningfield
Sep 10, 2002·Journal of the Experimental Analysis of Behavior·David ZieglerMark Galizio

Related Concepts

Cues
Discrimination (Process of Differentiation)
Dose-Response Relationship, Drug
Subcutaneous Injections
Morphine Sulfate (2: 1), Pentahydrate
Naloxone, (5 beta,9 alpha,13 alpha,14 alpha)-Isomer
Trexan

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Synthetic Genetic Array Analysis

Synthetic genetic arrays allow the systematic examination of genetic interactions. Here is the latest research focusing on synthetic genetic arrays and their analyses.

Neural Activity: Imaging

Imaging of neural activity in vivo has developed rapidly recently with the advancement of fluorescence microscopy, including new applications using miniaturized microscopes (miniscopes). This feed follows the progress in this growing field.

Computational Methods for Protein Structures

Computational methods employing machine learning algorithms are powerful tools that can be used to predict the effect of mutations on protein structure. This is important in neurodegenerative disorders, where some mutations can cause the formation of toxic protein aggregations. This feed follows the latests insights into the relationships between mutation and protein structure leading to better understanding of disease.

Congenital Hyperinsulinism

Congenital hyperinsulinism is caused by genetic mutations resulting in excess insulin secretion from beta cells of the pancreas. Here is the latest research.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Epigenetic Memory

Epigenetic memory refers to the heritable genetic changes that are not explained by the DNA sequence. Find the latest research on epigenetic memory here.

Cell Atlas of the Human Eye

Constructing a cell atlas of the human eye will require transcriptomic and histologic analysis over the lifespan. This understanding will aid in the study of development and disease. Find the latest research pertaining to the Cell Atlas of the Human Eye here.

Femoral Neoplasms

Femoral Neoplasms are bone tumors that arise in the femur. Discover the latest research on femoral neoplasms here.